The range of frontline therapy options for mantle cell lymphoma can influence subsequent treatment choices for patients with relapsed or refractory disease. Providers must determine initial treatment based on individual patient characteristics, while also factoring in future treatment options. In this episode, CANCER BUZZ speaks with Nirav Shah, MD, MSHP, associate professor of medicine at Medical College of Wisconsin and Kirollos Hanna, PharmD, BCOP, PCOP, FACCC, assistant professor of pharmacy at Mayo Clinic and director of pharmacy at Minnesota Oncology, about shared decision making in the management of relapsed or refractory mantle cell lymphoma.

"The key to all of this is good collaboration between the community and their affiliates… their partners and academics, or tertiary referral centers, to really engage… these patients in a collaborative format… it really takes a team, a village, to take care of complex mantle cell lymphoma patients. " –Dr. Nirav Shah, MD, MSHP

"We're not really seeing a lot of CAR T-cell therapy move in the frontline setting just yet, while there are a lot of ongoing clinical trials… Really, right now, it's going to be the patient characteristic: how well they did on frontline therapy, access to care, affordability, institutional preparedness… that would potentially… allow your patient to receive CAR T-cell therapy." –Kirollos Hanna, PharmD, BCPS, PCOP, FACCC

Nirav Shah, MD, MSHP Associate Professor of Medicine Medical College of Wisconsin Division of Hematology and Oncology

Milwaukee, Wisconsin

Kirollos Hanna, PharmD, BCPS, PCOP, FACCC

Assistant Professor of Pharmacy, Mayo Clinic

Director of Pharmacy

Minnesota Oncology

St. Paul, Minnesota

This project is made possible by funding and support provided by Eli Lilly and in collaboration with The Leukemia & Lymphoma Society.

Resources

Treatment for Relapsed/Refractory Mantle Cell Lymphoma Tip Sheet - ACCC

Relapsed/Refractory Mantle Cell Lymphoma Educational Video Series:

Update on New Therapies: https://vimeo.com/942756449

BTK Inhibitors in MCL: https://vimeo.com/942755401

R/R MCL Case Studies: https://vimeo.com/942754652

BTK Inhibitors Stretch Frontline Approaches in Mantle Cell Lymphoma – Targeted Oncology

Emerging Data Continue to Affect BTK Inhibitor Usage in Mantle Cell Lymphoma - OncLive

HCP Fact Sheet: Facts About CAR T-cell Therapy - https://www.lls.org/sites/default/files/2023-10/FSHP1_CART_Factsheet_June2022_rev.pdf

The CAR T-cell Therapy Process - https://www.lls.org/sites/default/files/2024-03/PS100_CART-CellTherapyProcessFlyer_0224.pdf

Patient-Caregiver CAR T-cell Therapy Facts - https://www.lls.org/sites/default/files/2024-04/FS27_CART_Fact_Sheet_0424_rev.pdf

Learn About CAR T-cell Therapy - https://www.lls.org/sites/default/files/2024-03/PS126_CART_ResourceCard_3_24.pdf

Mantle Cell Lymphoma Facts for Patients and Caregivers -The Leukemia & Lymphoma Society https://lls.org/sites/default/files/2023-08/FS4_Mantle_Cell_Facts_0423rev.pdf